Heavy Metal Or Aluminum Containing Patents (Class 552/504)
-
Patent number: 10316055Abstract: The present invention relates to a method of purification of compound of formula (I) which comprises the step of crystallization of compound of formula (I) from a composition comprising the compound of formula (I) and the compound of formula (II) and a specific solvent system containing ethanol, 1-propanol, 2-propanol, 2-methyl-1-propanol, 1-butanol or 2-butanol.Type: GrantFiled: November 28, 2016Date of Patent: June 11, 2019Assignee: DSM IP ASSETS B.V.Inventors: Jan Schuetz, Ralph Waechter
-
Patent number: 9802977Abstract: The present invention discloses a method for synthesizing 25-hydroxy cholesterol. The method is as below: subjecting 24-dehydrocholesterol derivative as a raw material, which undergoes an addition reaction with a hydroxyl containing reagent in an organic solvent under catalysis, and then hydrolyzing the reaction product and separating to obtain 25-hydroxy cholesterol. The present invention adopts hydroxyl containing reagents such as water, formic acid, acetic acid, propionic acid, butyric acid, benzoic acid, p-methyl benzoic acid to replace the commonly used extremely toxic reagents such as Cr reagent, Hg reagent and polyfluorinated acetone in the prior art. The raw materials of the present invention are easily available, and have low effect on environment. The operation and post treatment are convenient.Type: GrantFiled: May 22, 2015Date of Patent: October 31, 2017Assignees: ZHEJIANG UNIVERSITY OF TECHNOLOGY, ZHEJIANG GARDEN BIOCHEMICAL HIGH-TECH CO., LTD, HANGZHOU XIASHA BIOCHEMICAL TECH CO., LTDInventors: Can Jin, Weike Su, Ziqiang Wang, Jiangang Liu, Bin Sun, Wenhao Xu
-
Publication number: 20140274936Abstract: A coordination complex having a physiologically acceptable pKa includes a metal and a biologically active agent. The pKa of the coordination complex is less than the pKa of the biologically active agent. A pharmaceutical solution for treating a patient includes a coordination complex and water, wherein the coordination complex is at least partially soluble in the water at physiological pH and in a therapeutically efficacious concentration. A method for treating a patient includes administering a pharmaceutical solution including a coordination complex and water to a patient in need of a biologically active agent.Type: ApplicationFiled: May 29, 2014Publication date: September 18, 2014Applicant: SYNTHONICS, INC.Inventors: Thomas Piccariello, John D. Price, Robert A. Oberlender, Michaela E. Mulhare, Mary C. Spencer, Scott B. Palmer
-
Publication number: 20140046021Abstract: The molecular structures of metal-salen complexes which exerts pharmacological effects are clarified and the metal-salen complexes having such molecular structures and their derivatives are provided. A metal-salen complex compound is characterized in that a metal atom part in each of multiple molecules of the metal-salen complex or its derivative is multimerized via water.Type: ApplicationFiled: January 19, 2012Publication date: February 13, 2014Applicants: IHI CORPORATIONInventors: Yoshihiro Ishikawa, Haruki Eguchi
-
Publication number: 20130052131Abstract: Embodiments of the present disclosure, in one aspect, relate to a nanoparticle, methods of imaging a tumor, method of imaging a disease, method of treating a condition, disease, or related biological event, or the like.Type: ApplicationFiled: August 24, 2012Publication date: February 28, 2013Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Zhen Cheng, Kai Cheng
-
Publication number: 20120189571Abstract: The invention is directed to biocompatible conjugated polymer nanoparticles including a copolymer backbone, a plurality of sidechains covalently linked to said backbone, and a plurality of platinum compounds dissociably linked to said backbone. The invention is also directed to dicarbonyl-lipid compounds wherein a platinum compound is dissociably linked to the dicarbonyl compound. The invention is also directed to methods of treating cancer or metastasis. The methods includes selecting a subject in need of treatment for cancer or metastasis and administering to the subject an effective amount of any of the nanoparticles, compounds, or compositions of the invention.Type: ApplicationFiled: February 4, 2010Publication date: July 26, 2012Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL., INC.Inventors: Shiladitya Sengupta, Abhimanyu Paraskar, Shivani Soni, Sudipta Basu, Poulomi Sengupta
-
Publication number: 20120029167Abstract: A drug using the magnetic properties of a metal salen complex as represented by the following general formula in order to magnetize the intended drug by chemically binding the drug to a metal salen complex so that the drug can be delivered to the target diseased site. The drug can be delivered to the diseased site using the magnetic properties of the drug per se without using a carrier made of a magnetic substance as in the conventional methods.Type: ApplicationFiled: May 20, 2011Publication date: February 2, 2012Applicants: Yoshihiro Ishikawa, IHI CorporationInventors: Yoshihiro ISHIKAWA, Haruki Eguchi
-
Publication number: 20100160268Abstract: A pharmacologic agent for treating and/or preventing cancer, among other diseases and conditions, and particularly breast, prostate, and pancreatic cancer, in humans and animals. The novel pharmacologic agent is an isoflavonoid or isoflavonoid mimetic covalently attached to a cytotoxic pharmacophore that, preferably has the ability to conjugate with a metal salt to form a more potent metal complex, particularly a Cu(II) complex. The isoflavonoid or isoflavonoid mimetic may he non-fragmented steroidal hormone, such as progesterone which is structurally related to the isoflavone genistein, or a small molecule hormone mimetic, such as chromone. An illustrative non-fragmented steroidal embodiment is 17-acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,13,14,15, 16,17-tetradecahydrocyclopenta[a]phenanthren-3-thiosemicarbazone and its Cu(II) complex. Effective chromone analogs include the thiosemicarbazone and hydrazone analogs of 4-oxo-4H-chromene-3-carboxaldehyde and their Cu(IT) complexes.Type: ApplicationFiled: September 25, 2006Publication date: June 24, 2010Inventors: Sarkar Fazlul, Subhash Padhye
-
Publication number: 20090169484Abstract: The present invention provides a drug delivery system that overcomes conventional technical problems and that is readily put to practical use. Iron-salen complexes represented by General Formula (I) below. The invention renders iron-salen complexes magnetic, which can thus be used as drugs that can be delivered to affected areas in the body using the inherent magnetic properties of the drug without employing carriers composed of magnetic substances as has been done hitherto.Type: ApplicationFiled: June 26, 2008Publication date: July 2, 2009Applicants: IHI Corporation, Yoshihiro IshikawaInventors: Haruki Eguchi, Yoshihiro Ishikawa
-
Publication number: 20040235712Abstract: In part, the present invention is directed to coordination complexes comprising a therapeutic agent. In one aspect, the subject compositions comprise a platinum metal center and a covalently attached therapeutic agent.Type: ApplicationFiled: January 12, 2004Publication date: November 25, 2004Inventors: Stephen J. Lippard, Carmen M. Barnes, Ariel Haskel, Katie R. Barnes
-
Patent number: 6737417Abstract: The present invention provides a compound consisting of a moiety and a group chemically bonded to said moiety, wherein said moiety contains a compound having low activity following oral administration or its parent scaffold and said group has the following general formula (1): in which R1 represents a hydrogen atom, etc., R2 represents a C1-C7 halogenoalkyl group, etc., m represents an integer of 2 to 14, and n represents an integer of 2 to 7, or enantiomers of the compound, or hydrates or pharmaceutically acceptable salts of the compound or enantiomers thereof. The above compound is advantageous in pharmaceutical use because the group of general formula (1) allows compounds such as anti-estrogenic ones to show a significantly increased activity following oral administration when attached to the parent scaffolds of the compounds.Type: GrantFiled: June 13, 2002Date of Patent: May 18, 2004Assignee: Chugai Seiyaku Kabushiki KaishaInventors: JaeChon Jo, HeeAn Kwon, HyunSuk Lim, JaeYoung Choi, Kazumi Morikawa, Yoshitake Kanbe, Masahiro Nishimoto, MyungHwa Kim, Yoshikazu Nishimura
-
Patent number: 6720307Abstract: Novel analogs of fusidic acid are described with one or more carbohydrate units attached. Certain glycosylated analogs of fusidic acid have enhanced solubility properties in diluents or excipient of choice as compared to unmodified fusidic acid. Certain glycosylated analogs may be employed as chemotherapeutic agents and particular analogs may be useful for fighting anti-microbial infections.Type: GrantFiled: July 2, 2002Date of Patent: April 13, 2004Assignee: The University of MichiganInventors: Roeland Tuinman, Masato Koreeda, Brian Keith Shull
-
Publication number: 20040034216Abstract: A compound of formula (I) and pharmaceutical acceptable salts, solvates, stereoisomers and prodrugs thereof, in isolation or in mixture, wherein, independently at each occurrence: R1 and R2 are selected from hydrogen, oxygen so as to form nitro or oxime, amino, sulfate, and sulfonic acid, and organic groups having 1-30 carbons and optionally containing 1-6 heteroatoms selected from nitrogen, oxygen, phosphorous, silicon, and sulfur, where R1 and R2 may, together with the N to which they are both bonded, form a heterocyclic structure that may be part of an organic group having 1-30 carbons and optionally containing 1-6 heteroatoms selected from nitrogen, oxygen and silicon, and where R1 may be a 2, or 3 atom chain to numeral 2 so that —N—R1— forms part of a fused bicyclic structure to ring A; R3 and R4 are selected from direct bonds to 6 and 7 respectively so as to form carbonyl groups, hydrogen, or a protecting group such that R3 and/or R4 is part of hydroxyl or carbonyl protecting group; nuType: ApplicationFiled: March 13, 2003Publication date: February 19, 2004Inventors: Jeffrey R. Raymond, Claudia E. Kasserra, Yaping Shen
-
Publication number: 20040006051Abstract: 1Type: ApplicationFiled: March 27, 2003Publication date: January 8, 2004Applicant: Gervais BerubeInventor: Gervais Berube
-
Publication number: 20030220311Abstract: The compositions and methods disclosed herein provide heterobifunctional programmable genotoxic compounds that can be designed to kill selected cells present in a heterogenous cell population. The present compounds comprise a first agent that inflicts damage on cellular DNA, and a second agent that attracts a macromolecular cell component such as a protein, which in turn shields genomic lesions from repair. Unrepaired lesions therefore persist in the cellular genome and contribute to the death of selected cells. In contrast, lesions formed in nonselected cells, which lack the cell component, are unshielded and thus are repaired. As a result, compounds described herein are less toxic to nonselected cells. Compounds of this invention can be designed to cause the selective killing of transformed cells, viral-infected cells and the like.Type: ApplicationFiled: November 18, 2002Publication date: November 27, 2003Inventors: John M. Essigmann, Robert G. Croy, Kevin J. Yarema, Marshall Morningstar
-
Publication number: 20030113265Abstract: Compounds able to chelate paramagnetic metal ions and the use thereof as contrast agents in the technique known as “Magnetic Resonance Imaging” (M.R.I.), which consist of at least two chelating agents conjugated via a multivalent linker group, to a bile acid.Type: ApplicationFiled: August 27, 2002Publication date: June 19, 2003Inventors: Christoph De Haen, Andrea Beltrami, Enrico Cappelletti, Luciano Lattuada, Mario Virtuani
-
Publication number: 20010056074Abstract: The invention consists of a compound of the general formula (I) below: 1Type: ApplicationFiled: January 4, 2001Publication date: December 27, 2001Inventors: Jean-Jacques Yaouanc, Erwann Guenin, Jean-Claude Clement, Anne-Cecile Herve, Claude Ferec, Virginie Floch, Herve des Abbayes
-
Patent number: 5585468Abstract: This invention relates to chelating agents useful for coupling metal ions to biologically active molecules. In particular, substantial thioureas for chelating metals such as technetium are provided that can be conjugated to a targeting molecule such as an antibody, a peptide or a protein.Type: GrantFiled: June 27, 1994Date of Patent: December 17, 1996Assignee: Cytogen CorporationInventors: Daniel J. Coughlin, Benjamin A. Belinka, Jr.
-
Patent number: 5326856Abstract: This invention relates to chelating agents useful for coupling metal ions to biologically active molecules. In particular, isothiocyanate derived thiocarbonyls for chelating metals such as technetium are provided that can be conjugated to a targeting molecule such as an antibody, a peptide or a protein.Type: GrantFiled: April 9, 1992Date of Patent: July 5, 1994Assignee: Cytogen CorporationInventors: Daniel J. Coughlin, Benjamin A. Belinka, Jr.
-
Patent number: 5273971Abstract: There are provided 13-alkyl-11beta-phenyl-gonanes of formula I ##STR1## wherein Z is an oxygen atom or N--OH;R.sup.2 is alpha- or beta-position methyl or ethyl;R.sup.1 is selected from heteroaryl radicals, cycloalkyl radicals, cycloalkenyl radicals, aryl radicals, alkenyl radicals, and alkyl radicals where R.sup.2 is in the alpha-position and an ethyl radical where R.sup.2 is in the beta-position; andR.sup.3 and R.sup.4 are selected from one of two different groups of substituent pairs, the group from which the selection is made being determined by the position of R.sup.2.Type: GrantFiled: July 3, 1989Date of Patent: December 28, 1993Assignee: Schering AktiengesellschaftInventors: Stefan Scholz, Eckhard Ottow, Guenter Neef, Walter Elger, Sybille Beier, Krzysztof Chwalisz
-
Patent number: 5232915Abstract: 9.alpha.-Hydroxy-19,11.beta.-bridged steroids of general formula I ##STR1## are described. The more detailed meaning of A, B, R.sup.1, R.sup.2, G, Z, R.sup.4 --Y and R.sup.4' --Y' follows from the description. The steroids of general formula I have antigestagen and/or antiglucocorticoidal action and can be used for the production of pharmaceutical agents.Type: GrantFiled: January 14, 1992Date of Patent: August 3, 1993Assignee: Schering AktiengesellschaftInventors: Eckhard Ottow, Gunter Neef, Rudolf Wiechert, Walter Elger, Sybille Beier, Karl-Heinrich Fritzemeier
-
Patent number: 4975536Abstract: The present invention is a process for conversion of .DELTA..sup.16 -steroids (I) ##STR1## to the corresponding .DELTA..sup.17(20) -20-silyl ether (III) ##STR2## by reaction with (1) a preformed copper hydride or a metal hydride reducing agent in the presence of a copper species and (2) a silylating agent. The .DELTA..sup.17(20) -20-silyl ether (III) are useful intermediates in the preparation of steroids useful as pharmaceuticals.Type: GrantFiled: June 2, 1989Date of Patent: December 4, 1990Assignee: The Upjohn CompanyInventor: Kenneth P. Shephard
-
Patent number: 4945064Abstract: Estrane and androstane derivatives of formula I ##STR1## wherein X is bromine, iodine, triphenyltin or trialkyltin of 1 to 6 carbon atoms per alkyl radical,Y represents two hydrogen atoms or methylene,Z represents two hydrogen atoms, oxo or alkylenedioxy of 2 to 6 carbon atoms andV is ethylene, vinylene, 1,3-propylene or cyclopropylene,R.sub.1 is hydrogen or a hydrocarbon radical of up to 8 hydrocarbon atoms, optionally interrupted by an oxa group or substituted by an oxo group,R.sub.2 is methyl or ethyl,R.sub.3 and R.sub.4 represent a carbon-carbon bond or R.sub.3 is hydrogen and R.sub.4 is hydrogen or methyl,.DELTA.symbolizes a 4(5)-double bond if Z signifies two hydrogen atoms or an oxo group; or a 5(6)-double bond or, for the estrane derivatives of formula I, also a 5(10)-double bond, if Z is alkylenedioxy,are pharmacologically effective substances or intermediates for preparation thereof.Type: GrantFiled: January 19, 1988Date of Patent: July 31, 1990Assignee: Schering AktiengesellschaftInventors: Helmut Hofmeister, Henry Laurent, Paul E. Schulze, Klaus Annen, Rudolf Wiechert, Kunhard Pollow, Bernhard Manz, Hans-Joerg Grill
-
Patent number: 4937262Abstract: Derivatives of platinum group metals, particularly platinum itself, wherein the metal is linked to one or more pharmaceutically acceptable steroid, fatty acid or other lipophilic residues aiding transport of the metal across cell membranes in the body, particularly fatty acid amine or fatty acid amide groups ##STR1## where R is a hydrocarbon group, suitably of 10 to 30 carbon atoms. The derivatives are useful in the treatment of cancer.Type: GrantFiled: August 24, 1987Date of Patent: June 26, 1990Assignee: EFAMOL Ltd.Inventor: Bruce C. Davidson